| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Departments of Nuclear Medicine [M. J. D.], Medical Oncology [J. J. F.], Education and Research Center [D. R.], St. Vincent's Hospital, Dublin 4; St. Luke's Hospital, Dublin 6 [C. O.]; Department of Surgery, University College, Dublin 4 [N. O.] Ireland; and Department of Molecular Biology and Plant Physiology, University of Aarhus, Aarhus, Denmark [P. A.]
Urokinase plasminogen activator (UK-PA) is a serine protease implicated in cancer invasion and metastasis. In this investigation, patients with breast cancers containing high levels of UK-PA antigen had significantly higher risk of early disease recurrence and shorter overall survival than did patients with low levels of the protein. In univariate analysis, UK-PA was a more powerful discriminator for disease-free interval than axillary node status, tumor size, or estradiol receptor. For overall survival, UK-PA as a prognostic marker, was of similar magnitude to axillary node status but stronger than that of tumor size or estradiol receptor. In multivariate analysis, for both disease-free interval and survival, UK-PA was an independent risk factor, being independent of tumor size, axillary node status, and estradiol receptor. UK-PA appears to be a new and independent prognostic marker in breast cancer.
1 This work was supported with grants from Health Research Board of Ireland (M. J. D.), The Irish Cancer Society (M. J. D.), The Danish Cancer Society (P. A.), and The Danish Medical Research Council (P. A.).
2 To whom requests for reprints should be addressed, at Nuclear Medicine Department, St. Vincent's Hospital, Dublin 4, Ireland.
Received 12/12/89. Accepted 6/25/90.
This article has been cited by other articles:
|
|
 |
|
  E. Ortiz-Zapater, S. Peiro, O. Roda, J. M. Corominas, S. Aguilar, C. Ampurdanes, F. X. Real, and P. Navarro Tissue Plasminogen Activator Induces Pancreatic Cancer Cell Proliferation by a Non-Catalytic Mechanism That Requires Extracellular Signal-Regulated Kinase 1/2 Activation through Epidermal Growth Factor Receptor and Annexin A2 Am. J. Pathol., May 1, 2007; 170(5): 1573 - 1584. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. D. Maurer, J. H. Leupold, D. M. Schewe, T. Biller, R. E. Kates, H.-M. Hornung, U. Lau-Werner, S. Post, and H. Allgayer Analysis of Specific Transcriptional Regulators as Early Predictors of Independent Prognostic Relevance in Resected Colorectal Cancer Clin. Cancer Res., February 15, 2007; 13(4): 1123 - 1132. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Schewe, T. Biller, G. Maurer, I. A. Asangani, J. H. Leupold, E. R. Lengyel, S. Post, and H. Allgayer Combination Analysis of Activator Protein-1 Family Members, Sp1 and an Activator Protein-2{alpha}-Related Factor Binding to Different Regions of the Urokinase Receptor Gene in Resected Colorectal Cancers Clin. Cancer Res., December 15, 2005; 11(24): 8538 - 8548. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Shin, K. O. Kim, M. K. Kim, K. H. Lee, M. S. Hyun, K. J. Kim, J. H. Choi, and H. S. Song Expression of E-Cadherin and uPA and their Association with the Prognosis of Pancreatic Cancer Jpn. J. Clin. Oncol., June 1, 2005; 35(6): 342 - 348. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Sapi The Role of CSF-1 in Normal Physiology of Mammary Gland and Breast Cancer: An Update Experimental Biology and Medicine, January 1, 2004; 229(1): 1 - 11. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Daly, A. Makris, M. Reed, and C. E. Lewis Hemostatic Regulators of Tumor Angiogenesis: A Source of Antiangiogenic Agents for Cancer Treatment? J Natl Cancer Inst, November 19, 2003; 95(22): 1660 - 1673. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. V. Offersen, B. S. Nielsen, G. Hoyer-Hansen, F. Rank, S. Hamilton-Dutoit, J. Overgaard, and P. A. Andreasen The Myofibroblast Is the Predominant Plasminogen Activator Inhibitor-1-Expressing Cell Type in Human Breast Carcinomas Am. J. Pathol., November 1, 2003; 163(5): 1887 - 1899. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Schewe, J. H. Leupold, D. D. Boyd, E. R. Lengyel, H. Wang, K. U. Gruetzner, F. W. Schildberg, K. W. Jauch, and H. Allgayer Tumor-specific Transcription Factor Binding to an Activator Protein-2/Sp1 Element of the Urokinase-type Plasminogen Activator Receptor Promoter in a First Large Series of Resected Gastrointestinal Cancers Clin. Cancer Res., June 1, 2003; 9(6): 2267 - 2276. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Palmieri, S. Poggi, V. Ulivi, G. Casartelli, and P. Manduca Pro-collagen I COOH-terminal Trimer Induces Directional Migration and Metalloproteinases in Breast Cancer Cells J. Biol. Chem., January 31, 2003; 278(6): 3639 - 3647. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Castello, A. Estelles, C. Vazquez, C. Falco, F. Espana, S. M. Almenar, C. Fuster, and J. Aznar Quantitative Real-Time Reverse Transcription-PCR Assay for Urokinase Plasminogen Activator, Plasminogen Activator Inhibitor Type 1, and Tissue Metalloproteinase Inhibitor Type 1 Gene Expressions in Primary Breast Cancer Clin. Chem., August 1, 2002; 48(8): 1288 - 1295. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Heiss, E. H. Simon, B. C.M. Beyer, K. U. Gruetzner, A. Tarabichi, R. Babic, F. W. Schildberg, and H. Allgayer Minimal Residual Disease in Gastric Cancer: Evidence of an Independent Prognostic Relevance of Urokinase Receptor Expression by Disseminated Tumor Cells in the Bone Marrow J. Clin. Oncol., April 15, 2002; 20(8): 2005 - 2016. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Harbeck, R. E. Kates, and M. Schmitt Clinical Relevance of Invasion Factors Urokinase-Type Plasminogen Activator and Plasminogen Activator Inhibitor Type 1 for Individualized Therapy Decisions in Primary Breast Cancer Is Greatest When Used in Combination J. Clin. Oncol., February 15, 2002; 20(4): 1000 - 1007. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. S. Nielsen, F. Rank, J. M. Lopez, M. Balbin, F. Vizoso, L. R. Lund, K. Dano, and C. Lopez-Otin Collagenase-3 Expression in Breast Myofibroblasts as a Molecular Marker of Transition of Ductal Carcinoma in Situ Lesions to Invasive Ductal Carcinomas Cancer Res., October 1, 2001; 61(19): 7091 - 7100. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. van der Pluijm, B. Sijmons, H. Vloedgraven, C. van der Bent, J.-W. Drijfhout, J. Verheijen, P. Quax, M. Karperien, S. Papapoulos, and C. Lowik Urokinase-Receptor/Integrin Complexes Are Functionally Involved in Adhesion and Progression of Human Breast Cancer in Vivo Am. J. Pathol., September 1, 2001; 159(3): 971 - 982. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L.-Y. Luo, D. Katsaros, A. Scorilas, S. Fracchioli, R. Piccinno, I. A. Rigault de la Longrais, D. J. C. Howarth, and E. P. Diamandis Prognostic Value of Human Kallikrein 10 Expression in Epithelial Ovarian Carcinoma Clin. Cancer Res., August 1, 2001; 7(8): 2372 - 2379. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. N. Holten-Andersen, R. W. Stephens, H. J. Nielsen, G. Murphy, I. J. Christensen, W. Stetler-Stevenson, and N. Brunner High Preoperative Plasma Tissue Inhibitor of Metalloproteinase-1 Levels Are Associated with Short Survival of Patients with Colorectal Cancer Clin. Cancer Res., November 1, 2000; 6(11): 4292 - 4299. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Koli and J. Keski-Oja 1{{alpha}},25-Dihydroxyvitamin D3 and Its Analogues Down-Regulate Cell Invasion-associated Proteases in Cultured Malignant Cells Cell Growth Differ., April 1, 2000; 11(4): 221 - 229. [Abstract] [Full Text]
|
|
|
|
|
|
M. Los, S. Zeamari, J. A. Foekens, M. F. B. G. Gebbink, and E. E. Voest Regulation of the Urokinase-type Plasminogen Activator System by the von Hippel-Lindau Tumor Suppressor Gene Cancer Res., September 1, 1999; 59(17): 4440 - 4445. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. H. D. Nguyen, I. M. Hussaini, and S. L. Gonias Binding of Urokinase-type Plasminogen Activator to Its Receptor in MCF-7 Cells Activates Extracellular Signal-regulated Kinase 1 and 2 Which Is Required for Increased Cellular Motility J. Biol. Chem., April 3, 1998; 273(14): 8502 - 8507. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. H. Bugge, K. W. Kombrinck, Q. Xiao, K. Holmback, C. C. Daugherty, D. P. Witte, and J. L. Degen Growth and Dissemination of Lewis Lung Carcinoma in Plasminogen-Deficient Mice Blood, December 1, 1997; 90(11): 4522 - 4531. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. D. Lox, C. A. Ronaghan, E. Cobos, and R. H. Messer Tamoxifen-Induced Changes in the Plasma Fibrinolytic Factors in Menopausal Women with Breast Cancer Clinical and Applied Thrombosis/Hemostasis, October 1, 1997; 3(4): 234 - 238. [Abstract] [PDF]
|
|
|
|
|
|
R. W. Stephens, A. N. Pedersen, H. J. Nielsen, M. J. A. G. Hamers, G. Hoyer-Hansen, E. Ronne, E. Dybkjær, K. Dano, and N. Brunner ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients Clin. Chem., October 1, 1997; 43(10): 1868 - 1876. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. A. Hembrough, L. Li, and S. L. Gonias Cell-surface Cytokeratin 8Is the Major Plasminogen Receptor on Breast Cancer Cells and Is Required for the Accelerated Activation of Cell-associated Plasminogen by Tissue-type Plasminogen Activator J. Biol. Chem., October 11, 1996; 271(41): 25684 - 25691. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
